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High and low platelet reactivity on clopidogrel, prasugrel and ticagrelor in
acute coronary syndrome patients: insight from a real-life large cohort
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BACKGROUND Dual antiplatelet therapy with a P2Y12 inhibitor is
mandatory in acute coronary syndromes (ACS) undergoing angio-
plasty. New antiplatelet drugs prasugrel and ticagrelor offer more
efﬁcient inhibition compared to clopidogrel. Under P2Y12 inhibitor,
platelet reactivity (PR) assessment can predict ischemic and bleeding
events. The aim of our study was to compare PR in ACS patients on
P2Y12 inhibitors in a real-world setting.
METHODS Platelet reactivity (PR) was prospectively assessed in
consecutive patients with recurrent ACS or undergoing high-risk an-
gioplasty. PR was measured 24hrs after last intake of clopidogrel (C)
and prasugrel (P), and 12hrs for ticagrelor (T) by ﬂow cytometry
measured vasodilatator-stimulated phosphoprotein platelet reactivity
index (VASP-PRI) and light transmission agregometry with ADP 20mM
(LTA-ADP). High Platelet Reactivity (HPR) was deﬁned as VASP-
PRI>50% or LTA-ADP>65% (thresholds previously linked to clinical
events). Low Platelet Reactivity (LPR) was deﬁned as VASP-PRI<16%
or LTA-ADP<40%.
RESULTS Six hundred and nineteen patients treated with aspirin and
C (n¼269), P (n¼241) or T (n¼109) were included from 01/2011 to 07/
2013. Mean age was 6213yrs., 80% were men and 63% had STEMI.
Patients on C were older, more often women and admitted for
NSTEMI. Inﬂammatory parameters were lower in this subgroup (C).
Clinical and biological characteristics were similar between patients
on P and those on T. HPR was more frequent with C compared to P and
T and signiﬁcantly more frequent with P compared to T (Table 1). At
the opposite, LPR was signiﬁcantly more frequent in patients
treated with T. In multivariate analysis, the signiﬁcant predictor of
HPR with VASP was P (OR¼0.13-CI[0.08-0.22]) or T (OR¼0.01-[0.01-
0.09]). The signiﬁcant predictor of LPR with VASP was T (OR¼3.37-
[2.09-5.44]).
Table 1. Platelet reactivity assessment according to P2Y12 inhibitors and platelet function tests.HPR LPRVASP-PRI LTA-ADP VASP-PRI LTA-ADPClopidogrel 48% 37% 7% 14%Prasugrel 12%* 15%* 27%* 44%*Ticagrelor 1%*x 2%*x 55%*x 72%*x*p<0.05 vs clopidogrel; xp<0.05 vs prasugrel.
CONCLUSIONS This observational biological study conﬁrms a more
potent platelet inhibition of the new P2Y12 compared to clopidogrel,
mainly ticagrelor. The very high rate of LPR found with ticagrelor does
not match with the bleeding risk found in the PLATO trial.
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BACKGROUND Platelet a2A-Adrenergic Receptor(ARs) potentiates
epinephrine-induced platelet aggregation in response to sympathetic
stimulation. Genetic variants of the a2A -ARs are associated with
different antiplatelet reactivity. The effect of genetic variants of the
a2A -ARs on platelet reactivity and clinical outcomes has not yet been
reported in Chinese patients with dual antiplatelet therapy after
percutaneous coronary intervention. The aim of this study was to
investigate the effect of the a2A -ARs variants on platelet reactivity
and clinical outcomes in these patients.
METHODS 1056 patients with dual antiplatelet therapy after percu-
taneous coronary intervention were enrolled in a single-center reg-
istry. All known a2A -ARs genetic variants including rs11195419,
rs3750625, rs13306146, rs553668 were detected by the ligase detection
reaction and the antiplatelet effect was assessed by thromboelastog-
raphy. Primary clinical endpoints included cardiovascular death,
nonfatal myocardial infarction, target vessel revascularization, and
stent thrombosis. The secondary clinical endpoints were angina
recurrence, readmission and in-stent restenosis. The follow-up pe-
riods were 6 months and 12 months.
RESULTS The frequencies of the a2A -ARs variants were respectively
18.09%, 17.17%, 25.43%, 43.71%. Genotypic distributions of all the
variants were in conformity with Hardy-Weinberg equilibrium
except rs13306146. Platelet ADP inhibition were signiﬁcantly
different among wild type, heterozygote and homozygote mutated
groups carrying rs11195419 genetic variant (53.8629.78% vs.
50.7227.80% vs. 39.2819.53%, P¼0.012) or rs3750625 genetic
variant (53.7129.84% vs. 50.9327.55% vs. 37.52418.60%,
P¼0.007) and the homozygote mutated groups have the lowest ADP
inhibition of the three groups variants. However, there were no
signiﬁcant differences in ADP inhibition among the rs553668 geno-
type groups (50.2027.83% vs. 54.0929.41% vs. 52.1130.00%,
P¼0.158). At the multivariable analysis, the presence of the
rs11195419 (95%CI: -0.062– -2.070, P¼0.039) or rs3750625 (95%CI:
-0.068– -2.281, P¼0.023) genetic variants was an independent pre-
dictor of the ADP inhibition. However, there were no signiﬁcant
differences in the composite clinical outcome across the rs11195419,
rs3750625, rs553668 genotype groups at both 6 and 12 months
follow-up period(P>0.05).
CONCLUSIONS The presence of mutated alleles of a2A -AR genetic
variants (rs11195419, rs3750625) except rs553668 is associated with
decreased ADP-induced platelet reactivity in Chinese patients with
DAPT after percutaneous coronary intervention. However, none of the
a2A -AR genetic variants signiﬁcantly inﬂuenced the clinical outcomes
of DAPT in these patients.
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BACKGROUND Higher loading and maintenance dose Clopidogrel
overcomes delayed and often variable effect of standard dose Clopi-
dogrel in majority of the patients. However, data comparing this
strategy with potent alternatives such as Ticagrelor & Prasugrel are
scarce.
B80 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5METHODS We aimed to compare efﬁcacy & safety of Prasugrel, Tica-
grelor, standard & high dose Clopidogrel in patients undergoing PCI.
PubMed, EMBASE, CENTRAL and clinicaltrials.gov were searched for
studies comparing Prasugrel, Ticagrelor, standard dose (SD) & high
dose (HD) Clopidogrel in patients undergoing PCI. Frequentist and
Bayesian random effect network meta-analyses were performed be-
sides random effect direct pairwise comparisons. Statistical analysis
was conducted using WinBugs and Stata software. Ranking of treat-
ments are based on surface under cumulative ranking curves (SUCRA)
derived from Bayesian analysis. SUCRA values provide chances of
being best drug in form of percentage (%).
RESULTS Thirty trials, with 34, 563 person years of follow up data
after PCI, were included in the analysis. Prasugrel (86%) emerged
as best drug to prevent deﬁnite or probable stent thrombosis,
followed by Clopidogrel HD (66%) and Ticagrelor (44%), with Clo-
pidogrel SD being the worst. Myocardial infarction was least likely
to be prevented by Clopidogrel SD (0%) after PCI, and rest three
were superior to it (Prasugrel 74%; Clopidogrel 70%; Ticagrelor
56%). Clopidogrel SD (18%) was least effective in preventing car-
diovascular deaths after PCI. Prasugrel (73%) was likely most
effective in preventing cardiovascular deaths followed by Ticagrelor
(62%) and Clopidogrel HD (47%). Ticagrelor (68%) reduced all-cause
mortality by a small margin compared to rest of treatments (Pra-
sugrel 50%; Clopidogrel 48%; Clopidogrel 34%). Clopidogrel SD
(79%), followed by Clopidogrel HD (53%) and Ticagrelor (48%),
resulted in signiﬁcantly lower TIMI major bleeding complications
compared to Prasugrel. Analysis of any bleeding revealed similar
trend. Clopidogrel HD performed better than Prasugrel in terms of
bleeding complications. Results of direct pairwise comparison and
network meta-analysis were consistent in the direct of overall ef-
fect (Figure).
CONCLUSIONS Prasugrel is most effective drug to prevent post PCI
ischemic events but at the expense of higher bleeding. Ticagrelor
followed by Clopidogrel HD appears to strike the right balance be-
tween efﬁcacy & safety.
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BACKGROUND Primary angioplasty is the best reperfusion treatment
in ST elevated myocardial infarction. The number of elderly patients
(> 75 years) undergoing primary angioplasty is progressively
increasing as population is ageing. The optimal antithrombotic ther-
apy during the procedure (bivalirudin vs. unfractioned heparin with
or without abciximab) is not deﬁned for this important subgroup of
patients.
METHODS Retrospective consecutive registry conducted in 31 centers
of patients > 75 years with ST elevation myocardial infarction un-
dergoing primary angioplasty.
RESULTS A total of 3,126 pts have been included, 2,029 (64.9%)
treated only with UFH, 750 (24%) with UFH+abciximab, 319 (10.2%)
with bivalirudin only and 28 (0.9%) with bivalirudin+abciximab.
Three groups were deﬁned: BIV (319), UFH (2.029) and UFH-A (750)
with mean ages 81.25, 81.6 4.7 and 79.6 4.3 years respectively
(p<0.001).. Outcomes at 12 months were the following: survival free of
cardiac death and MI was 85.6%, 80% and 83.4% (p¼0.01) in BIV, UFH
and UFH-A groups and TLR was 2.7%, 3% and 1.4% (p¼0.1) respec-
tively. Incidences of deﬁnite or probable stent thrombosis were 2.8%,
2.5% and 2.3% (p¼0.2) and incidences of bleeding BARC > 2 were
0.8%, 1.3% and 1.5% (p¼0.1) respectively.
CONCLUSIONS The most common antithrombotic treatment in pri-
mary angioplasty of the very elderly is based on UFH (89%) with the
use of abciximab in a 24% of cases. The use of bivalirudin was asso-
ciated with the lowest incidence of cardiac death and MI with no in-
crease in stent thrombosis. The rate of severe bleeding (BARC >2) was
comparable.
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BACKGROUND Some patients have high residual platelet reactivity
on clopidogrel after coronary intervention and risk of thbombotic
events is high. The aim of the study was to investigate safety and
efﬁcacy of policosanol in patients with high on-treatment platelet
reactivity after drug-eluting stent implantation.
